priors.science/reviews/targeted-therapy-prostate-cancer

Targeted Therapy Prostate Cancer

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

17claims tracked
250primary papers reviewed
4 Jun 2026latest evidence review
Weeklyre-scored against new papers
11 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAbiraterone overall survival benefit in metastatic hormone-sensitive prostate cancerAdt IntensifyEstablished90%20
StableEnzalutamide overall survival benefit in metastatic castration-resistant prostate cancerArpiEstablished89%20
StableEnzalutamide metastasis-free survival benefit in non-metastatic castration-resistant prostate cancerNmcrpcEstablished89%20
StableEnzalutamide or darolutamide overall survival in metastatic hormone-sensitive prostate cancerAdt IntensifyEstablished88%20
StableAbiraterone overall survival benefit post-docetaxel in metastatic castration-resistant prostate cancerArpiEstablished88%20
StableLu-PSMA-617 overall survival in metastatic castration-resistant prostate cancer (VISION)PsmaEstablished88%20
StableOverall survival benefit of androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerNmcrpcEstablished87%20
StableOlaparib radiographic progression-free survival in homologous recombination repair-mutant metastatic castration-resistant prostate cancerPARPEstablished87%20
StableRadium-223 overall survival in bone-only metastatic castration-resistant prostate cancerBoneEstablished86%20
StablePSMA PET staging superior to conventional imagingPsmaEstablished86%20
StablePARP plus androgen receptor inhibitor combination in metastatic castration-resistant prostate cancerPARPLikely74%20
StableAndrogen receptor splice variant 7 predicts androgen receptor inhibitor resistanceResistanceLikely73%20
StablePembrolizumab activity in microsatellite instability-high or high tumour mutational burden prostate cancerResistanceLikely72%20
StableAndrogen receptor inhibitor sequence cross-resistanceArpiLikely70%20
StablePTEN loss and androgen receptor inhibitor resistance in metastatic castration-resistant prostate cancerResistanceLikely70%20
StableRucaparib benefit in non-BRCA homologous recombination repair metastatic castration-resistant prostate cancerPARPUncertain58%20
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic